Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jose Teodoro Junior has a total of 213 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Viral inhibition of the anaphase promoting complex enhances replication by elevating nucleotide pools

    by Owen J. Chen, Cynthia Y. Feng, Paola Blanchette, Reese Jalal Ladak, Maximilian A. Crosby, Mariana de Sá Tavares Russo, Yilin Wang, Cristina Fernandez, Yingke Liang, David M. Sharon, et al.

    The anaphase promoting complex/cyclosome (APC/C) is a large, ubiquitin ligase and a central regulator of cell cycle progression. By targeting key substrates for degradation during mitosis and G1 phase, the APC/C coordinates metabolic fluctuations that occur during the cell cycle. A diverse range of viruses have convergently evolved mechanisms to bind and inhibit the APC/C; however, a molecular understanding for these interactions has never been demonstrated. Here, we use chicken anemia virus (CAV), a small single-stranded DNA virus encoding only three proteins, to demonstrate the importance of viral APC/C inhibition during replication. We show that the Vp3 protein of CAV inhibits the APC/C, causing a dramatic mitotic arrest during infection. The mutant virus lacking Vp3 is defective for replication and can be rescued by APC/C inhibition. Metabolomic profiling during CAV infection revealed that Vp3 expression mediates a broad increase in nucleotide pools. Moreover, viral inhibition of the APC/C resulted in stabilization of enzymes required for nucleotide biosynthesis. These findings suggest that the APC/C is a general target of many viruses to elevate nucleotide levels and facilitate viral genome replication.

  • Open Access

    Viral inhibition of the anaphase promoting complex enhances replication by elevating nucleotide pools

    by Owen J. Chen, Cynthia Y. Feng, Reese Jalal Ladak, Maximilian A. Crosby, Mariana de Sá Tavares Russo, Yilin Wang, Paola Blanchette, Yingke Liang, David M. Sharon, Mohamed Moustafa-Kamal, et al.

    The anaphase promoting complex/cyclosome (APC/C) is a large, ubiquitin ligase and a central regulator of cell cycle progression. By targeting key substrates for degradation during mitosis and G1 phase, the APC/C coordinates metabolic fluctuations that occur during the cell cycle. A diverse range of viruses have convergently evolved mechanisms to bind and inhibit the APC/C; however, a molecular understanding for these interactions has never been demonstrated. Here, we use chicken anemia virus (CAV), a small single-stranded DNA virus encoding only three proteins, to demonstrate the importance of viral APC/C inhibition during replication. We show that the Vp3 protein of CAV inhibits the APC/C, causing a dramatic mitotic arrest during infection. Mutant virus lacking Vp3 are defective for replication and can be rescued by APC/C inhibition. Metabolomic profiling during CAV infection revealed that Vp3 expression mediates a broad increase in nucleotide pools. Moreover, viral inhibition of the APC/C resulted in stabilization of enzymes required for nucleotide biosynthesis. These findings suggest that the APC/C is a general target of many viruses to elevate nucleotide levels and facilitate viral genome replication. Author Summary: Viruses dramatically reshape the cells they infect in order to replicate. To do this efficiently, many viruses disrupt the host’s normal control systems, particularly those that regulate cell growth and division. One such system is the anaphase promoting complex/cyclosome (APC/C), a key cellular machine that controls when specific proteins are broken down during the cell cycle. Surprisingly, a wide range of viruses—including adenovirus, HIV, human papillomavirus, herpesvirus, and others—have been shown to interfere with the APC/C. Until now, however, it was unclear why so many unrelated viruses target this same pathway. In our study, we used chicken anemia virus (CAV), one of the smallest known animal viruses, as a simple model to uncover the underlying mechanism. CAV produces just three proteins, one of which—called VP3—strongly inhibits the APC/C. We found that this inhibition increases the availability of nucleotides, the basic building blocks needed to copy viral DNA. By disrupting normal cell cycle control, the virus effectively redirects cellular resources toward its own replication. These findings reveal APC/C inhibition as a common and powerful strategy used by diverse viruses, offering new insight into how viruses exploit host cells and highlighting potential targets for future antiviral therapies.


  • Open Access

    Cleavage of the V-ATPase associated prorenin receptor is mediated by PACE4 and is essential for growth of prostate cancer cells

    by Amro H. Mohammad, Frédéric Couture, Isabelle Gamache, Owen Chen, Wissal El-Assaad, Nelly Abdel-Malak, Anna Kwiatkowska, William Muller, Robert Day, Jose G. Teodoro

    Phosphatase and tensin homolog (PTEN) mutation is common in prostate cancer during progression to metastatic and castration resistant forms. We previously reported that loss of PTEN function in prostate cancer leads to increased expression and secretion of the Prorenin Receptor (PRR) and its soluble processed form, the soluble Prorenin Receptor (sPRR). PRR is an essential factor required for proper assembly and activity of the vacuolar-ATPase (V-ATPase). The V-ATPase is a rotary proton pump required for the acidification of intracellular vesicles including endosomes and lysosomes. Acidic vesicles are involved in a wide range of cancer related pathways such as receptor mediated endocytosis, autophagy, and cell signalling. Full-length PRR is cleaved at a conserved consensus motif (R-X-X-R↓) by a member of the proprotein convertase family to generate sPRR, and a smaller C-terminal fragment, designated M8.9. It is unclear which convertase processes PRR in prostate cancer cells and how processing affects V-ATPase activity. In the current study we show that PRR is predominantly cleaved by PACE4, a proprotein convertase that has been previously implicated in prostate cancer. We further demonstrate that PTEN controls PRR processing in mouse tissue and controls PACE4 expression in prostate cancer cells. Furthermore, we demonstrate that PACE4 cleavage of PRR is needed for efficient V-ATPase activity and prostate cancer cell growth. Overall, our data highlight the importance of PACE4-mediated PRR processing in normal physiology and prostate cancer tumorigenesis.


  • Open Access

    Data from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer

    by Amro H. Mohammad, Sung-Hoon Kim, Nicholas Bertos, Wissal El-Assaad, Ipshita Nandi, Harvey Smith, Jieyi Yang, Owen J. Chen, Isabelle Gamache, Trisha Rao, et al.

    PTEN loss-of-function contributes to hyperactivation of the PI3K pathway and to drug resistance in breast cancer. Unchecked PI3K pathway signaling increases activation of the mechanistic target of rapamycin complex 1 (mTORC1), which promotes tumorigenicity. Several studies have suggested that vacuolar (H+)–ATPase (V–ATPase) complex activity is regulated by PI3K signaling. In this study, we showed that loss of PTEN elevated V–ATPase activity. Enhanced V–ATPase activity was mediated by increased expression of the ATPase H+ transporting accessory protein 2 (ATP6AP2), also known as the prorenin receptor (PRR). PRR is cleaved into a secreted extracellular fragment (sPRR) and an intracellular fragment (M8.9) that remains associated with the V–ATPase complex. Reduced PTEN expression increased V–ATPase complex activity in a PRR-dependent manner. Breast cancer cell lines with reduced PTEN expression demonstrated increased PRR expression. Similarly, PRR expression became elevated upon PTEN deletion in a mouse model of breast cancer. Interestingly, concentration of sPRR was elevated in the plasma of patients with breast cancer and correlated with tumor burden in HER2-enriched cancers. Moreover, PRR was essential for proper HER2 receptor expression, localization, and signaling. PRR knockdown attenuated HER2 signaling and resulted in reduced Akt and ERK 1/2 phosphorylation, and in lower mTORC1 activity. Overall, our study demonstrates a mechanism by which PTEN loss in breast cancer can potentiate multiple signaling pathways through upregulation of the V–ATPase complex.Implications:Our study contributed to the understanding of the role of the V–ATPase complex in breast cancer cell tumorigenesis and provided a potential biomarker in breast cancer.

  • Open Access

    Supplemental Table 1 A from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer

    by Amro H. Mohammad, Sung-Hoon Kim, Nicholas Bertos, Wissal El-Assaad, Ipshita Nandi, Harvey Smith, Jieyi Yang, Owen J. Chen, Isabelle Gamache, Trisha Rao, et al.

    Clinical parameters of patients from whom tissue microarrays were acquired for PRR staining.

  • Open Access

    Supplemental Figure Legends 1-3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer

    by Amro H. Mohammad, Sung-Hoon Kim, Nicholas Bertos, Wissal El-Assaad, Ipshita Nandi, Harvey Smith, Jieyi Yang, Owen J. Chen, Isabelle Gamache, Trisha Rao, et al.

    Figure S1. This figure compares ATP6AP2 expression in normal and tumour human prostate and breast tissues. Figure S2. This figure contains bright-field counterparts of LysoTracker images. This figure also contains HER2 immunostaining after PRR knockdown in SKBR3 cells. Figure S3. This figure contains clinical data that complement the observations made in Figure 4.

  • Open Access

    Supplemental Table 3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer

    by Amro H. Mohammad, Sung-Hoon Kim, Nicholas Bertos, Wissal El-Assaad, Ipshita Nandi, Harvey Smith, Jieyi Yang, Owen J. Chen, Isabelle Gamache, Trisha Rao, et al.

    Sequence of qPCR, siRNA, and shRNA used

  • Open Access

    Supplemental Figure 2 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer

    by Amro H. Mohammad, Sung-Hoon Kim, Nicholas Bertos, Wissal El-Assaad, Ipshita Nandi, Harvey Smith, Jieyi Yang, Owen J. Chen, Isabelle Gamache, Trisha Rao, et al.

    This figure contains bright-field counterparts of LysoTracker images. This figure also contains HER2 immunostaining after PRR knockdown in SKBR3 cells.

  • Open Access

    Supplemental Table 1 B from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer

    by Amro H. Mohammad, Sung-Hoon Kim, Nicholas Bertos, Wissal El-Assaad, Ipshita Nandi, Harvey Smith, Jieyi Yang, Owen J. Chen, Isabelle Gamache, Trisha Rao, et al.

    Clinical parameters of patients from whom tissue microarrays were acquired for P-Akt staining

  • Open Access

    Supplemental Figure 3 from Elevated V–ATPase Activity Following PTEN Loss Is Required for Enhanced Oncogenic Signaling in Breast Cancer

    by Amro H. Mohammad, Sung-Hoon Kim, Nicholas Bertos, Wissal El-Assaad, Ipshita Nandi, Harvey Smith, Jieyi Yang, Owen J. Chen, Isabelle Gamache, Trisha Rao, et al.

    This figure contains clinical data that complement the observations made in Figure 4.